Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Galena Biopharma Inc    GALE

Delayed Quote. Delayed  - 09/29 10:00:00 pm
0.3285 USD   -5.25%
09/29 Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim..
09/28 GALENA BIOPHARM : Presents GALE-301 Folate Binding Protein Expressio..
09/27 Galena Biopharma Presents GALE-301 Folate Binding Protein Express..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/23/2016 09/26/2016 09/27/2016 09/28/2016 09/29/2016 Date
0.3622(c) 0.345(c) 0.3404(c) 0.3467(c) 0.3285(c) Last
2 344 703 2 781 191 1 693 469 3 777 575 3 173 124 Volume
-2.50% -4.75% -1.33% +1.85% -5.25% Change
More quotes
Financials ($)
Sales 2016 -
EBIT 2016 -34,7 M
Net income 2016 -24,3 M
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -31,9 M
Net income 2017 -29,8 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 0
Capi. / Sales2017 0
Capitalization 70,5 M
More Financials
Company
Galena Biopharma, Inc. engages as a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs.It focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of... 
Sector
Pharmaceuticals
Calendar
11/07Earnings Release
More about the company
Surperformance© ratings of Galena Biopharma Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on GALENA BIOPHARMA INC
09/29 Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data..
09/28 GALENA BIOPHARMA : Presents GALE-301 Folate Binding Protein Expression Data at t..
09/27 Galena Biopharma Presents GALE-301 Folate Binding Protein Expression Data at ..
09/20 Galena Biopharma to Present at the Sachs Associates 16th Annual Biotech in Eu..
09/16 GALENA BIOPHARMA : Presents Preclinical NeuVax (nelipepimut-S) Data in Ovarian a..
09/14 Galena Biopharma to Present at the 2016 Aegis Growth Conference
09/13 Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data in O..
09/12 Galena Biopharma Expands GALE-401 Intellectual Property Protection with Paten..
09/09 Galena Biopharma to Present at the Rodman & Renshaw 18th Annual Global Invest..
09/08 GALENA BIOPHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
More news
Sector news : Pharmaceuticals - NEC
07:26aDJNovo Nordisk Announces Job Cuts
09/29DJGLAXOSMITHKLINE : Appoints New Consumer Healthcare Chief
09/29DJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 Best And Worst Performing Stocks Of 2016
08/09 Galena Biopharma's (GALE) CEO Mark Schwartz on Q2 2016 Results - Earnings Cal..
08/09 Galena Biopharma beats by $0.09
08/08 Notable earnings after Tuesday?s close
07/12 Galena issues over 3.6M shares of stock to resolve outstanding issues
Advertisement
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | GALE | US3632561086 | 4-Traders
Full-screen chart
Technical analysis trends GALENA BIOPHARMA INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 1,13 $
Spread / Average Target 245%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark W. Schwartz President, Chief Executive Officer & Director
Sanford J. Hillsberg Chairman
Gavin S. Choy Senior VP-Clinical Sciences & Operations
Bijan Nejadnik Chief Medical Officer & Executive Vice President
Stephen S. Galliker Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GALENA BIOPHARMA INC-77.65%70
JOHNSON & JOHNSON14.16%320 836
ROCHE HOLDING LTD.-11.51%216 029
NOVARTIS AG-10.14%209 049
PFIZER INC.3.22%202 108
MERCK & CO., INC.17.21%171 194
More Results